Healthcare / Diagnostics & ResearchTokyo
$2500.00
-16.00 (-0.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.1B · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$25.0B
P/E
12.5x
↓EV/EBITDA
5.0x
↓ROE
7.6%
↑Gross Margin
30.8%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.7%
FCF CAGR
-16.4%
FCF margin
2.6%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $43.31B · net income $1.92B · FCF $1.13B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $43.31B | $43.31B | $43.01B | $46.91B | $50.01B |
| Net Income | $1.92B | $1.92B | $1.67B | $2.26B | $3.53B |
| EBITDA | $3.72B | $3.72B | $3.56B | $4.75B | $6.55B |
| EPS | 180.81 | 180.81 | 150.90 | 214.03 | 336.99 |
| Gross Margin | 30.8% | 30.8% | 30.0% | 31.2% | 34.6% |
| Operating Margin | 5.4% | 5.4% | 5.0% | 6.6% | 11.0% |
| Net Margin | 4.4% | 4.4% | 3.9% | 4.8% | 7.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.03 | 0.11 | 0.17 |
| Current Ratio | 2.37 | 2.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.13B | $1.13B | $2.19B | $708.0M | $1.94B |
| Returns | |||||
| ROE | 7.6% | 7.6% | 6.4% | 8.5% | 15.0% |
| Valuation | |||||
| P/E | 12.50 | 12.50 | 14.98 | 9.05 | 6.19 |
| EV/EBITDA | 4.99 | 4.99 | 4.42 | 2.24 | 2.33 |
| P/B | 1.05 | 1.05 | 0.96 | 0.77 | 0.93 |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | -8.3% | -6.2% | — |
| EPS Growth | 19.8% | 19.8% | -29.5% | -36.5% | — |
| Dividend Yield | 5.1% | 5.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
7.1%
EPS terminal req.
$221.83
Spread vs growth
12.8%
5Y implied EPS CAGR
8.2%
EPS terminal req.
$268.42
Spread vs growth
11.6%
10Y implied EPS CAGR
9.1%
EPS terminal req.
$432.29
Spread vs growth
10.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.7%
Start / end P/E
15.3x → 13.8x
EPS bridge
150.90 → 180.81
Residual
-1.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.